0.00Open0.02Pre Close0 Volume92 Open Interest38.00Strike Price0.00Turnover117.45%IV31.35%PremiumAug 30, 2024Expiry Date0.00Intrinsic Value100Multiplier4DDays to Expiry0.02Extrinsic Value100Contract SizeAmericanOptions Type0.0163Delta0.0114Gamma1447.25Leverage Ratio-0.0137Theta0.0000Rho23.55Eff Leverage0.0012Vega
Pfizer Stock Discussion
This stock is still undervalued and has more upside than tech stocks.
"GeoVax’s COVID-19 vaccine candidates, which can induce strong antibody and T cell responses against the variants of the SARS-CoV-2 virus, also offers the possibility of protection against Mpox and smallpox diseases, further differentiating GEO-CM04S1 as compared to current mRNA-based COVID-19 vaccines. Such attributes ma...
Vaccines will be available in the coming days, drugmakers say
The Food and Drug Administration on Thursday gave Pfizer Inc. and Moderna Inc. approval for updated COVID-19 vaccines, as a summer wave of the virus is still rolling across the country.
Pfizer and partner BioNTech's (BNTX) Comirnaty vaccine and Moderna's Spikevax were approved for people 12 years old and up, the FDA said, while versions of the shots for children between 6 months and 11 years old were granted emergency...
It is possible to see a three white soldiers pattern tomorrow. The stock is on the up trend.
The chart shows a hammer last Friday. The stock is likely to reach the bottom and it’s rebounding from low. Next hit point is 29.18.
According to the Futubull Financial News APP, the US Food and Drug Administration (FDA) is preparing to approve an updated version of the Covid vaccine targeted at the current epidemic virus strain as early as this week to deal with the largest summer epidemic in the United States in nearly two years. It is reported that the FDA will approve the updated mRNA vaccine targeting the KP.2 virus strain developed by Pfizer (PFE.US)/BioNTech (BNTX.US) and Moderna (MRNA.US). It is not y...
I added some shares at 28.21 and 28.15 last night to dca.
No comment yet